Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2020 Jul 6;16(2):437–453. doi: 10.1007/s11481-020-09936-5

Figure 1. Development of immunodeficiency in gp120tg mice treated with LP-BM5.

Figure 1.

Young (8-10 week old) and old (4-5 months old) gp120tg+ and gp120tg− mice were euthanized at 12 weeks post-LP-BM5 treatment (5xl04 pfu, i.p.). Spleen weight/body weight ratio (A), serum IgM (B), and serum IgG2a (C) are shown in interaction plots. Data are presented as mean ± SEM; n=7-16/group. Two-way ANOVA followed by Tukey post hoc test were performed. * indicates the main effect of LP-BM5 (p<0.05). # p<0.05 between the indicated groups regardless of LP-BM5 treatment. % p<0.05 between the indicated group and all other groups under LP-BM5 treatment condition only.